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64 ±. 22 for WTP £0,0. 81±0.16 for £ 1 to 49,. 81±15 for £ 50 to 99,. 76±. 16 for £100 to 
199,. 79± for £ 200 to 299,. 71±. 19 for £300 or more. Patients spent a mean of 50±134 
minutes (HDSS = 2), 65±119 minutes (HDSS = 3) and 161±293 minutes (HDSS = 4) for 
daily management of hyperhidrosis. WTP showed the lowest correlation to disease 
severity. ConClusions: The current study underscores the multidimensionality 
of the burden of hyperhidrosis, with all aspects showing greater impairment with 
greater disease severity. Health utility and daily time spent in managing the condi-
tion offered significant discrimination of patients.
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Subjective exPectationS RegaRding Life exPectancy and HeaLtH-
ReLated QuaLity of Life in ModeRate to SeveRe PSoRiaSiS PatientS
Rencz F.1, Gulacsi L.1, Remenyik É.2, Szegedi A.2, Holló P.3, Kárpáti S.3, Péntek M.1, Brodszky V.1
1Corvinus University of Budapest, Budapest, Hungary, 2University of Debrecen, Debrecen, 
Hungary, 3Semmelweis University, Budapest, Hungary
objeCtives: To assess psoriasis patients’ subjective expectations regarding their 
future health-related quality of life (HRQOL) and life-expectancy, and to explore 
variables associated with under- or overestimating behaviour. Methods: A cross-
sectional questionnaire survey of adult moderate to severe psoriasis patients was 
carried out. Patients were asked to indicate the age they expect themselves to live. 
HRQOL expectations were measured by the EQ-5D descriptive system for 6 months 
ahead and for future ages of 60,70,80 and 90, respectively. Current health state was 
evaluated with EQ-5D and visual analogue scale (EQ VAS), Dermatology Life Quality 
Index (DLQI) and Psoriasis Area and Severity Index (PASI). Results: Overall 167 
patients (71% males) were included in the analysis with mean age of 50.38±12.35 
years, mean EQ-5D, EQ VAS, DLQI and PASI scores were 0.71±0.30,65.3±21.08,5. 89±7.10 
and 7.82±10.13, respectively. Currently 56% of the patients were on biological therapy. 
Patients expected 0.1±0.23 mean improvement in EQ-5D scores within 6 months 
(p< 0.001); inverse or palmoplantar psoriasis, and using only topical treatment or 
initiation of the first biological at the time of the survey were likely associated with 
higher expectations. Males overestimated their life-expectancy by 2.94±11.86 years 
whereas females underestimated by 5.23±9.34 years (p< 0.001) compared to the gen-
der- and age-matched statistical life-expectancy. Expected mean EQ-5D scores for 
ages from 60 to 90 were: 0.56±0.48,0. 38±0.50,0. 15±0.55, and -0.17±0.54 (p< 0.001), 
respectively that are lower than the general population norms in Hungary. Both for 
6 months ahead and older ages, expected EQ-5D correlated moderately with current 
EQ-5D and EQ VAS and only weakly with DLQI and PASI (p< 0.05). ConClusions: 
Patients expected considerable improvement in their HRQOL for the near future and 
large-scale deterioration for older ages. Exploring unrealistic expectations might help 
to prevent dissatisfaction with treatment benefits and to improve compliance.
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tHe deciSion Making PRoceSS in Receiving bone conduction iMPLantS 
(bci) foR SingLe Sided deafneSS
Kosaner M., Urban M.
VIBRANT MED-EL Hearing Technology GmbH, Innsbruck, Austria
objeCtives: The main objective of this study was to evaluate the process in which 
patients with single sided deafness proceed to receive bone conduction implants. 
Factors contributing to decisions for or against implantation were also com-
piled. Methods: Using a comprehensive search strategy, several online databases 
were searched to identify studies published since 2002. Research involving adults 
and children with single sided deafness (SSD); and reporting on patient preference 
for receiving BCIs were included. Screening of titles, and data extraction and quality 
assessment of full papers were undertaken by one reviewer with any uncertainties 
resolved by consultation with a second reviewer. Results: 16 studies were identi-
fied covering a total of 914 individuals diagnosed with SSD. All patients who trialled 
a CROS device preferred to receive a BCI. Acceptance of new generation CROS devices 
is suggested to be better but still low. Following a BCI Headband trial 19% to 77% of 
patients across studies (mean 51%) proceeded to receive a BCI. When reported, the 
most common reason for rejecting implantation was insufficient benefit with the 
Headband in speech in noise or insufficient/no relief from tinnitus. Studies assess-
ing factors in decision making found that age, gender, aetiology, duration of hearing 
loss or the presence of contralateral hearing loss did not differ between individu-
als who decide for or against implantation. One study so far suggests the role of 
transcranial attenuation at 2 kHz and tinnitus loudness to play a role in decision 
making. ConClusions: When given the option to trial traditional treatments and 
BCI simulators/Headbands many patients with SSD reject BCIs. This research high-
lights the importance of providing such trials before implantation. It is still unknown 
which aspects play a role in decision making and identifying better candidates.
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tHe buRden of cHRonic uRticaRia in euRoPe: a SySteMatic LiteRatuRe 
Review
Betoret I.1, Lambert C.1, Paravisini A.1, Tribaldos M.2, Paz S.3, Lizán L.2
1Novartis Farmaceutica, Barcelona, Spain, 2Outcomes 10, Castellon, Spain, 3Outcomes’10, 
Castellon, Spain
objeCtives: To synthesize and analyze the available information on the burden of 
chronic urticaria (CU) [Patients’ Reported Outcomes (PROs): Health related quality 
of life (HRQoL), adherence, satisfaction, preferences, use of medical resources and 
costs] in Europe. Methods: A systematic review on PROs and costs of CU was 
performed. International (Pub Med, WOK, Scopus, Cochrane Library) and national 
(CSIC-IME, IBECS, MEDES) databases were consulted. Original articles, narrative/sys-
tematic reviews of studies developed in Europe, until December 2013 were retrieved. 
Editorials, letters/commentaries, and efficacy or economic evaluations of specific 
drugs were excluded. Costs were updated to € , 2013. Results: 9 studies assessed 
HRQoL (3, Germany; 1, France, Greece, Italy, Spain, UK, Germany/France, respectively) 
and 1 satisfaction with treatments (Germany/France). No studies on adherence or 
preferences for treatments were identified. The CU-Q2oL instrument, (0-100, higher 
value, worse HRQoL), was the most frequently used (n= 4). Scores ranged from 18.4 
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HeaLtH ReLated QuaLity of Life in PatientS witH actinic keRatoSiS 
- ReSuLtS fRoM PatientS tReated in deRMatoLogy SPeciaLiSt caRe in 
denMaRk
Ragnarson Tennvall G.1, Norlin J.M.2, Malmberg I.3, Erlendsson A.4, Hædersdal M.4
1IHE, The Swedish Institute for Health Economics, Lund, Sweden, 2LEO Pharma A/S, Ballerup, 
Denmark, 3LEO Pharma AB, Malmö, Sweden, 4Bispebjerg Hospital, Copenhagen, Denmark
objeCtives: Actinic keratosis (AK) is a common skin condition associated with 
cumulative sun exposure that may progress to non-melanoma skin cancer. The 
disease can potentially influence Health Related Quality of Life (HRQoL), but stud-
ies of HRQoL in patients with AK are limited. The objective was to analyze HRQoL 
in patients with AK using generic and disease-specific HRQoL instruments and to 
analyze the relationship between instruments. Methods: AK patients who vis-
ited dermatological clinics in Denmark were included in an observational, cross-
sectional, study in a multi-center setting. Dermatologists assessed AK severity 
and patients completed: Actinic Keratosis Quality of Life Questionnaire (AKQoL), 
Dermatology Life Quality Index (DLQI), EQ-5D (5L), and EuroQoL Visual Analogue 
Scale (EQ-VAS). Results: A total of 312 patients from 10 clinics were included in 
the analyses. In general, patients with AK reported impaired HRQoL. The mean 
values (possible range) were: AKQoL 6.7 (0-27), DLQI 2 (0-30), EQ-5D-5L 0.88 (0-1), 
and EQ-VAS 79 (0-100). HRQoL was least affected in patients with mild actinic dis-
ease, whereas patients with severe actinic damage suffered from further impaired 
HRQoL (mean AKQoL 10.1 and DLQI 4.6). The correlation between DLQI and AKQoL 
was moderate (0.52), whereas the correlations between DLQI and EQ-5D (-0.36) and 
between AKQoL and EQ-5D (-0.10) were weak. ConClusions: All patients with AK 
had impaired HRQoL. Patients with severe actinic damage were considerably more 
affected than those with mild disease. Correlations between instruments demon-
strate that they are complementary as they measure different aspects of HRQoL 
and are used for different purposes. EQ-5D is essential for economic evaluations, 
the DLQI is responsive to changes in relation to treatment and AKQoL captures 
important aspects related to sun damaged skin.
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categoRicaL HeaLtH StateS in cHRonic SPontaneouS uRticaRia 
(cSu) baSed on tHe weekLy uRticaRia activity ScoRe (uaS7): aRe tHey 
diStinct, diScRiMinative, and RePRoducibLe?
Stull D.E.1, McBride D.1, Gimenez-Arnau A.2, Grattan C.3, Khalil S.4, Balp M.M.4
1RTI Health Solutions, Manchester, UK, 2Hospital del Mar and Universitat Autònoma, Barcelona, 
Spain, 3Norfolk and Norwich University Hospital, Norfolk, UK, 4Novartis Pharma AG, Basel, 
Switzerland
objeCtives: Specific ranges of scores reflecting patient severity or changes in 
severity have not been established for average daily urticaria activity summed 
over 7 days (UAS7; range= 0-42), a common measure for assessing CSU disease 
activity. This study evaluates whether five non-overlapping health states derived 
from the continuous UAS7 score can discriminate between patients with different 
severities of urticaria and are reproducible across multiple studies. Methods: 
Data come from three randomised, double-blind, placebo-controlled Phase III 
clinical trials evaluating the effect of omalizumab on symptoms of patients with 
refractory CSU. Five CSU health states were defined: Urticaria-Free (UAS7= 0); Well-
Controlled Urticaria (UAS7= 1-6); Mild Urticaria (UAS7= 7-15); Moderate Urticaria 
(UAS7= 16-27); Severe Urticaria (UAS7= 28-42). Comparison variables included the 
Dermatology Life Quality Index (DLQI), a 10-item dermatologic QoL instrument 
(range= 0-30; higher scores= greater QoL impairment); patient diary questions ask-
ing about sleep and activity interference; presence of angioedema; and number 
of diphenhydramine 25mg pills taken in previous 24 hours. Analyses established 
whether different UAS7 health states showed different values on comparison 
variables. Analyses were replicated across the trials at baseline and weeks 12,24, 
and 40 (ASTERIA I and GLACIAL) and baseline and weeks 12 and 28 (ASTERIA II).  
Results: Mean values for comparison variables were lowest (zero or very 
close to zero) for patients who were Urticaria-Free and highest for those with 
Severe Urticaria. For Well-Controlled and Mild Urticaria comparison variable 
values increased. Larger increases in values occurred for Moderate and Severe 
Urticaria. Changes in categorical health state severity were highly related to cat-
egorical changes in DLQI (p< 0.001 for all trials and time points). ConClusions: 
Categorical UAS7 health states show meaningful differences in mean values on 
comparison variables and are highly related to established levels of effect on 
dermatological QoL. Categorical UAS7 health states could be informative about 
subgroups for economic models and useful for clinical practice.
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tHe buRden of PRiMaRy HyPeRHidRoSiS on tHe Patient: eQ-5d-5L 
utiLitieS, wiLLingneSS to Pay and daiLy tiMe SPent in Managing tHe 
condition
Kamudoni P.1, Salek M.S.1, Mueller B.2
1Cardiff University, Cardiff, UK, 2Riemser Pharma GmbH, Greifswald - Insel Riems, Germany
objeCtives: The objective of this study was to estimate the burden associated 
with primary hyperhidrosis by assessing patient’s health utilities, willingness 
to pay (WTP) for a complete cure and daily time spent in managing the condi-
tion. Methods: The data used in this study were collected under a longitudinal 
multi-stage research undertaken to develop and validate a new HRQoL instrument 
from patients with hyperhidrosis recruited through online social networking com-
munities (Hyperhidrosis support group UK and International hyperhidrosis society) 
from January to August 2013. Only the baseline assessment is used in this analy-
sis. Disease severity was measured using the Hyperhidrosis Disease Severity Scale 
(2 = for tolerable sweating, 3 = …barely tolerable sweating, 4 = intolerable sweating). 
The EuroQoL 5D-5L was used for assessing health utility index. Results: EQ-5D 
health utility index was lower in patients with more severe hyperhidrosis [mean 
utility value = . 85± 0.13 for HDSS = 2,0. 8±. 15 for HDSS = 3, and 0.69±. 2 for HDSS 
= 4, chi-square = 25.86, df = 2, p < 0.001]. Further, the health utility index was. 
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40.4±17.5 years with 76% males, respectively. Amongst the Hungarian patients 18% 
used none or only topical therapy in the last 12 months, 31% systemic non-bio-
logical treatment and 52% biologicals whereas in Iran 48% of the patients applied 
only topicals and 39% treated with non-biological systematic therapy. Mean EQ-5D, 
DLQI and PASI of the Hungarian and the Iranian sample were 0.69±0.3, 6.29±7.3, 
8.01±10, and 0.62±0.4, 10±6.5, 13±8.3, respectively. In both countries psoriasis of the 
neck and/or décolletage was associated with the greatest HRQOL reduction using 
either instrument (p< 0.05). Regarding clinical types, in Hungary the palmoplan-
tar involvement while in Iran nail psoriasis patients reported the worst general 
HRQOL (mean EQ-5D scores: 0.36±0.3 and 0.47±0.4). Correlation between EQ-5D 
and DLQI was found very similar across the two countries (rs= -0.43- and -0.44, 
p< 0.001), but EQ-5D showed significant correlation with PASI only in Hungary 
(rs= -0.43, p< 0.001). Strong positive correlation was identified between DLQI and 
PASI in both countries but only in those patients who received systemic therapy: 
Iran (rs= 0.72, p< 0.001) and Hungary (systemic non-biological: rs= 0.65, p< 0.001, 
biological: rs= 0.76, p< 0.001). ConClusions: Our results suggest that disease 
severity, treatments, and country-specific differences might lead to variations in 
the relationship between the outcome measures used in psoriasis.
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How can tHe QuaLity of Life in Hand eczeMa QueStionnaiRe (QoLHeQ) 
be inteRPReted? a banding Study
Ofenloch R.F.1, Weisshaar E.1, Dumke A.-K.2, Molin S.3, Diepgen T.L.1, Apfelbacher C.4
1University Hospital Heidelberg, Heidelberg, Germany, 2University Hospital Jena, Jena, Germany, 
3University Hospital Munich, Munich, Germany, 4UR - University of Regensburg, Regensburg, 
Germany
objeCtives: The Quality of Life in Hand Eczema Questionnaire (QOLHEQ) is a disease-
specific instrument to assess health-related Quality of Life (HRQOL) in hand eczema 
(HE) patients. The QOLHEQ assesses four domains of HRQOL: (a) symptoms, (b) emo-
tions, (c) functioning and (d) treatment/prevention. The QOLHEQ total-score ranges 
from 0-127 points. The aim of this study was to assign bands of the QOLHQ-score 
to an anchor question (AQ) on HE severity to aid the interpretation of the QOLHEQ-
score. Methods: Data was drawn from the German validation study of the QOLHEQ. 
We calculated median, mean and mode of the AQ for 30 categories of the QOLHEQ-
score to devise separate sets of bands. Weighted kappa was calculated in order to 
identify the set of bands with the best agreement between QOLHEQ and AQ. Results: 
Overall n= 316 HE patients were included in the study. Their mean age was 46.7 years 
(SD= 12.9) and 54.1% of the sample were female. With a weighted kappa of 0.54 the 
best agreement was found for the following band: QOLHEQ< 9 = minimal impairment; 
QOLHEQ 9-25 = slight impairment; QOLHEQ 25-58 = moderate impairment; QOLHEQ 
59-79 = severe impairment; QOLHEQ> 79 = very severe impairment. ConClusions: 
This is the first study which uses an anchor-based approach in order to devise a 
banding for the QOLHEQ-score. This banding represents a standardized means of 
interpreting the QOLHEQ total score. Further studies are needed to explore which 
banding may be adequate for different language version of the QOLHEQ.
PSS51
factoRS conditioning HeaLtH ReLated QuaLity of Life in PatientS 
witH PSoRiaSiS in euRoPe: a SySteMatic Review of tHe LiteRatuRe
Obradors M.1, Figueras M.1, Paz S.2, Comellas M.3, Lizán L.3
1Novartis Farmaceutica S. A., Barcelona, Spain, 2Outcomes’10, Castellon, Spain, 3Outcomes 10, 
Castellon, Spain
objeCtives: To identify conditioning factors of Health Related Quality of Life 
(HRQoL) of patients with psoriasis as reported in the literature in the last 5 years 
in Europe. Methods: Electronic databases [PubMed, ISI-WOK, Cochrane Library, 
MEDES, CSIC-IME, IBECS] and grey literature [Google Scholar], were searched to 
identify studies written in English or Spanish on HRQoL in patients with psoriasis, 
published in Europe between January 1, 2009 and December 31, 2013. Bibliographic 
references were hand searched. Editorials, letters, commentaries, opinion papers 
and studies related to specific treatments were excluded. Results: 27 stud-
ies accomplished the inclusion criteria. Most of the publications (66.7%, n= 18) 
were cross-sectional studies; 25.9% (n= 7) had a prospective design while 7.4% 
(n= 2) were retrospective. 12 studies analyzed the relation between HRQOL and 
demographic characteristics, determining in 75% and 50% of them, there was a 
relation between sex (women) and age (younger patients) with poorer HRQoL. 
3 publications demonstrated the HRQoL impairment associated with visibility of skin 
lesions. 4 studies appraised the relationship between disease activity and HRQoL 
determining a more compromised HRQOL in those patients with active psoriasis. 
Disease Severity was the most frequent assessed factor, being studied in 13 publica-
tions, describing in 92% of them that patients with higher PASI had worse HRQoL. 2 
articles indicated that disease symptoms as skin discomfort and pruritus were ele-
ments that negatively influenced the HRQoL of these patients. Emotional disturbances 
were identified as predictors of poorer HRQOL in 5 studies. 3 publications determined 
that the use of biologic therapy contributed to improve HRQoL. ConClusions: 
HRQoL has been broadly addressed in patients with psoriasis in Europe. Several 
disease- and patient-related factors contributed to its deterioration. Therapeutic 
measures with proved effectiveness in controlling disease symptoms and reducing 
PASI should be considered in patients with severe disease who have a relation with 
poorer HRQoL.
SenSoRy SySteMS diSoRdeRS – Health care use & Policy Studies
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coSt-effectiveneSS and vaLue of infoRMation anaLySeS of 
nutRitionaL SuPPoRt in PReventing PReSSuRe uLceRS in HigH RiSk 
HoSPitaLiSed PatientS
Tuffaha H.W.1, Shelley R.2, Chaboyer W.2, Gordon L.G.1, Scuffham P.A.1
1Griffith University, Meadowbrook, Australia, 2Griffith University, Gold Coast, Australia
(Greece) to 42.8 (Germany) revealing an acceptable perception of HRQoL. Sleep, itch-
ing/embarrassment and mental health were the HRQoL dimensions most impaired. 
Patients taking prescription drugs were more satisfied than those taking over the 
counter (p< 0.01). Severely ill patients were willing to change therapies if new, more 
effective alternatives became available (p< 0.05). Only 1 study assessed the costs of 
CU in Europe while another one described the use of medical resources. CU total 
cost in France was € 2,139.48 per patient/year. Patients lost 2.2 working days/month, 
being productivity losses 92% of total costs. CU patients were mostly cared for a 
dermatologist according to findings in Germany. A mean of 11.7 (SD: 11.5) visits/
month to the dermatology clinic were reported. ConClusions: PROs and costs 
in CU are infrequently addressed in the literature. Findings show patients reduced 
HRQoL and their willingness for more effective therapies. Frequent medical visits 
and loss of productivity make CU a burdensome disease in European countries.
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a Review of Patient RePoRted outcoMeS (PRoS) in PSoRiaSiS accoRding 
to tHe food and dRug adMiniStRation (fda) PRo guidance cRiteRia
Cheng R.
Covance Market Access Services, Inc., San Diego, CA, USA
objeCtives: Psoriasis is a chronic inflammatory skin condition that affects an 
estimated 4.5 to 7.5 million people in the United States. Numerous clinical trials 
have been conducted in psoriasis, many of which have included general derma-
tologic or psoriasis-specific PROs as study outcome measures. Commonly used 
PROs in these trials include the Dermatology Life Quality Index (DLQI), Psoriasis 
Disability Index (PDI), Psoriasis Life Stress Inventory (PLSI), Psoriasis Quality of Life 
Questionnaire (PQOL-12), and Skindex. This study assessed how well the develop-
ment and validation process of psoriasis-specific PROs align with the FDA PRO 
guidance. Methods: We reviewed the development and validation studies of the 
five PROs to assess if they align with the FDA PRO guidance criteria with regard to: 
(1) content validity, including patient input in concept elicitation, item generation, 
and cognitive debriefing; and (2) psychometric testing, including construct validity, 
internal-consistency and test-retest reliability, and responsiveness. Results: The 
PDI was developed without patient input in terms of concept elicitation, item gen-
eration, or cognitive debriefing. Variability and oftentimes inadequately documented 
evidence of patient input for concept elicitation, item generation, and cognitive 
debriefing were observed for the other four PROs. Test-retest reliability was not 
evaluated in the PLSI. Evidence of responsiveness was not available for three of the 
PROs. ConClusions: Based on this review, additional qualitative and quantitative 
research is needed to eliminate the identified gaps before these PROs could fulfill 
the FDA guidance for inclusion as a measure for a PRO label claim.
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cuRRent ManageMent and baRRieRS to tReatMent foR wet age-
ReLated MacuLaR degeneRation (waMd): PeRSPectiveS fRoM PatientS 
and caRegiveRS
Varano M.1, Eter N.2, Winyard S.3, Wittrup-Jensen K.U.4, Heraghty J5
1Fondazione G. B. Bietti-IRCCS, Rome, Italy, 2University of Muenster, Muenster, Germany, 3Royal 
National Institute of Blind People, London, UK, 4Bayer Pharma AG, Berlin, Germany, 5Macular 
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objeCtives: The aim of this global survey was to evaluate the management of 
wet age-related macular degeneration (wAMD) from a patient/caregiver perspec-
tive. Methods: Patients with a wAMD diagnosis and current or prior use of intravit-
real injections and caregivers from nine countries (Australia, Brazil, Canada, France, 
Germany, Italy, Japan, Spain, and the UK) completed a questionnaire. Results: 910 
patients and 890 caregivers were surveyed. 55% of patients had wAMD in 1 eye and 
64% had been receiving intravitreal injections for > 1 year. Many caregivers were a 
child/grandchild of the patient (47%), or partner (23%); only 7% were a professional 
caregiver. Most (73%) patients visited a health care professional (HCP) within 1 
month of first noticing a change in vision; 41% of patients who delayed visiting 
a HCP thought the symptoms would resolve. Following diagnosis, 54% of patients 
began treatment immediately, and a further 37% scheduled an appointment within 
1–3 weeks. 52% of patients reported a temporary improvement or stabilization in 
vision as a result of current treatment, and 22% reported a return to pre-diagnosis 
vision or that their vision was still improving. Most patients and caregivers reported 
a number of obstacles in managing wAMD, including the treatment itself (35% and 
39%, respectively), treatment costs (28% and 29%), and finding the right treatment 
options (27% and 31%). Additionally, 27% of caregivers found the patient’s treat-
ment extremely inconvenient with 57% of employed (non-professional) caregivers 
having to take time off work or miss personal obligations. 16% of patients missed 
a HCP appointment because their caregiver was unable to take them (26%), fear of 
injections (21%), illness (19%), forgetfulness (15%), inconvenience (10%), costs (6%), 
and discomfort of injections (3%). ConClusions: Many patients and caregivers 
identified a number of obstacles in managing wAMD. These included the treatment 
itself (patients and caregivers) and loss of productivity (non-professional caregivers).
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a coMaPRative cRoSS-SectionaL Study on HeaLtH-ReLated QuaLity of 
Life in PSoRiaSiS fRoM HungaRy and iRan
Moradi M., Rencz F.
Corvinus University of Budapest, Budapest, Hungary
objeCtives: To compare health-related quality of life (HRQOL) of Hungarian and 
Iranian psoriasis patients and to analyze possible differences in the relationship 
between EuroQol 5 dimensions (EQ-5D), Dermatology Life Quality Index (DLQI) 
and Psoriasis Area and Severity Index (PASI). Methods: Same cross-sectional 
questionnaire survey was carried out in two countries. Altogether 200 adult pso-
riasis patients enrolled from two Hungarian university clinics and 62 from an 
Iranian clinic. Besides HRQOL assessment, data on demographics, applied treat-
ments, affected body sites and clinical types were collected. Results: Mean age 
of the Hungarian and Iranian patients were 51.2 ±12.9 years with 69% males, and 
